Literature DB >> 10723139

Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase.

R Honda1, H Yasuda.   

Abstract

We previously showed that oncoprotein MDM2 has ubiquitin ligase activity toward tumor suppressor p53. In that paper, we showed very weak homology in the carboxyl terminal portion between MDM2 and E6AP (HECT domain). We mutated the cysteine residue (C464) corresponding to the residue essential for the ubiquitin ligase activity of E6AP and this mutation diminished the ligase activity of MDM2. The cysteine residue described above is also one of the cysteine residues that form the RING finger domain of MDM2. We tried to find out whether the diminishing of the activity by the mutation is attributable to the disruption of the RING finger domain or not. When the ring finger domain of MDM2 was deleted, the truncation mutant did not have the ubiquitin ligase activity. When we mutated the seven cysteine residues of RING finger domain of MDM2 in the carboxyl terminus, the disruption of each residue in the RING finger completely diminished the ubiquitin ligase activity of MDM2 toward MDM2 itself and toward tumor suppressor p53. These data indicate that the RING finger domain in MDM2 is essential for its ubiquitin ligase activity toward p53 and itself.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10723139     DOI: 10.1038/sj.onc.1203464

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  130 in total

1.  The RING-H2 finger protein APC11 and the E2 enzyme UBC4 are sufficient to ubiquitinate substrates of the anaphase-promoting complex.

Authors:  M Gmachl; C Gieffers; A V Podtelejnikov; M Mann; J M Peters
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

Review 2.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

3.  Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms.

Authors:  R Stad; N A Little; D P Xirodimas; R Frenk; A J van der Eb; D P Lane; M K Saville; A G Jochemsen
Journal:  EMBO Rep       Date:  2001-10-17       Impact factor: 8.807

Review 4.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

5.  In vivo action of the HRD ubiquitin ligase complex: mechanisms of endoplasmic reticulum quality control and sterol regulation.

Authors:  R G Gardner; A G Shearer; R Y Hampton
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

6.  Involvement of the DNA repair protein hHR23 in p53 degradation.

Authors:  Sandra Glockzin; Francois-Xavier Ogi; Arnd Hengstermann; Martin Scheffner; Christine Blattner
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

7.  Critical role for a central part of Mdm2 in the ubiquitylation of p53.

Authors:  Erik Meulmeester; Ruth Frenk; Robert Stad; Petra de Graaf; Jean-Christophe Marine; Karen H Vousden; Aart G Jochemsen
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

8.  Critical contribution of the MDM2 acidic domain to p53 ubiquitination.

Authors:  Hidehiko Kawai; Dmitri Wiederschain; Zhi-Min Yuan
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

9.  Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation.

Authors:  Jayne M Stommel; Geoffrey M Wahl
Journal:  EMBO J       Date:  2004-03-18       Impact factor: 11.598

Review 10.  HECT and RING finger families of E3 ubiquitin ligases at a glance.

Authors:  Meredith B Metzger; Ventzislava A Hristova; Allan M Weissman
Journal:  J Cell Sci       Date:  2012-02-01       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.